US Pharma MarketingAstraZeneca’s $800M bet undermined by immunogenicity in phase 3
AstraZeneca’s $800M bet undermined by immunogenicity in phase 3 is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Immunogenicity dragged on the efficacy of AstraZeneca’s rare endocrine disorder prospect in a phase 3 trial, causing the $800 million molecule’s response rate to fall short of the bar set by Ascendis Pharma’s Yorvipath.
Source: FierceBiotech